Cell therapy startup bit.bio adds $100M+ to its coffers and some impressive names to its board of directors

Bit.bio CEO Mark Kotter says the last major revolution in biopharma occurred around the 1980s, when antibodies — or, as some

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cell ther­a­py start­up bit.bio adds $100M+ to its cof­fers and some im­pres­sive names to its board of di­rec­tors